Orexin/Hypocretin Type 2 Receptor (HCRTR2) Gene as a Candidate Gene in Sertraline-Associated Insomnia in Depressed Patients

References

• Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Eng J Med. 2006;354(12):1231–1242. doi:10.1056/NEJMoa052963
   PubMed Web of Science ®Google Scholar
• Aguglia E, Casacchia M, Cassano GB, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol. 1993;8(3):197–202. doi:10.1097/00004850-199300830-000108263318
   PubMed Web of Science ®Google Scholar
• Liu X, Buysse DJ, Gentzler AL, et al. Insomnia and hypersomnia associated with depressive phenomenology and comorbidity in childhood depression. Sleep. 2007;30(1):83–90. doi:10.1093/sleep/30.1.8317310868
   PubMed Web of Science ®Google Scholar
• Siegel JM. The neurotransmitters of sleep. J Clin Psychiatry. 2004;65(Suppl 16):4–7.
   PubMed Web of Science ®Google Scholar
• Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98(3):365–376. doi:10.1016/S0092-8674(00)81965-010458611
   PubMed Web of Science ®Google Scholar
• Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999;98(4):437–451. doi:10.1016/S0092-8674(00)81973-X10481909
   PubMed Web of Science ®Google Scholar
• de Lecea L, Sutcliffe JG. The hypocretins and sleep. FEBS J. 2005;272(22):5675–5688. doi:10.1111/j.1742-4658.2005.04981.x16279933
   PubMed Web of Science ®Google Scholar
• De Lecea L, Huerta R. Hypocretin (orexin) regulation of sleep-to-wake transitions. Front Pharmacol. 2014;12(5):16.
   Google Scholar
• Chen Q, de Lecea L, Hu Z, Gao D. The hypocretin/orexin system: an increasingly important role in neuropsychiatry. Med Res Rev. 2015;35(1):152–197.25044006
   PubMed Web of Science ®Google Scholar
• de Lecea L. Optogenetic control of hypocretin (orexin) neurons and arousal circuits. InSleep Neuronal Plas Brain Funct. 2014;25:367–378.
   Google Scholar
• Jennings KJ, de Lecea L. Hypocretins (Orexins): Twenty Years of Dissecting Arousal Circuits. InThe Orexin/Hypocretin System. Academic Press; 2019 1 1:1–29.
   Google Scholar
• Bayer L, Eggermann E, Saint-Mleux B, et al. Selective action of orexin (hypocretin) on nonspecific thalamocortical projection neurons. J Neurosci. 2002;22(18):7835–7839. doi:10.1523/JNEUROSCI.22-18-07835.200212223534
   PubMed Web of Science ®Google Scholar
• Brown RE, Sergeeva O, Eriksson KS, Haas HL. Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. Neuropharmacology. 2001;40(3):457–459. doi:10.1016/S0028-3908(00)00178-711166339
   PubMed Web of Science ®Google Scholar
• Jacobs BL, Fornal CA. Activity of brain serotonergic neurons in the behaving animal. Pharmacol Rev. 1991;43(4):563–578.1775508
   PubMed Web of Science ®Google Scholar
• Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LH, Guan XM. Distribution of orexin receptor mRNA in the rat brain. FEBS Lett. 1998;438(1–2):71–75. doi:10.1016/S0014-5793(98)01266-69821961
   PubMed Web of Science ®Google Scholar
• Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001;435(1):6–25. doi:10.1002/cne.119011370008
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Fujiki N, Nakajima T, et al. Fluctuation of extracellular hypocretin‐1 (orexin A) levels in the rat in relation to the light–dark cycle and sleep–wake activities. Eur J Neurosci. 2001;14(7):1075–1081. doi:10.1046/j.0953-816x.2001.01725.x11683899
   PubMed Web of Science ®Google Scholar
• Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci. 2005;25(28):6716–6720. doi:10.1523/JNEUROSCI.1887-05.200516014733
   PubMed Web of Science ®Google Scholar
• Fujiki N, Yoshida Y, Ripley B, Honda K, Mignot E, Nishino S. Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. Neuroreport. 2001;12(5):993–997. doi:10.1097/00001756-200104170-0002611303775
   PubMed Web of Science ®Google Scholar
• Grady SP, Nishino S, Czeisler CA, Hepner D, Scammell TE. Diurnal variation in CSF orexin-A in healthy male subjects. Sleep. 2006;29(3):295–297. doi:10.1093/sleep/29.3.29516553014
   PubMed Web of Science ®Google Scholar
• Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011;10(51):243–266. doi:10.1146/annurev-pharmtox-010510-100528
   Web of Science ®Google Scholar
• Brisbare-Roch C, Dingemanse J, Koberstein R, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 2007;13(2):150–155. doi:10.1038/nm154417259994
   PubMed Web of Science ®Google Scholar
• Randeva HS, Karteris E, Grammatopoulos D, Hillhouse EW. Expression of orexin-A and functional orexin type 2 receptors in the human adult adrenals: implications for adrenal function and energy homeostasis. J Clin Endocrinol Metab. 2001;86(10):4808–4813. doi:10.1210/jcem.86.10.792111600545
   PubMed Web of Science ®Google Scholar
• Karteris E, Randeva HS, Grammatopoulos DK, Jaffe RB, Hillhouse EW. Expression and coupling characteristics of the CRH and orexin type 2 receptors in human fetal adrenals. J Clin Endocrinol Metab. 2001;86(9):4512–4519. doi:10.1210/jcem.86.9.784911549701
   PubMed Web of Science ®Google Scholar
• Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron. 2003;38(5):715–730. doi:10.1016/S0896-6273(03)00330-112797957
   PubMed Web of Science ®Google Scholar
• Hawcutt DB, Thompson B, Smyth RL, Pirmohamed M. Paediatric pharmacogenomics: an overview. Arch Dis Child. 2013;98(3):232–237. doi:10.1136/archdischild-2012-30285223196740
   PubMed Web of Science ®Google Scholar
• Rainero I, Gallone S, Valfre W, et al. A polymorphism of the hypocretin receptor 2 gene is associated with cluster headache. Neurology. 2004;63(7):1286–1288. doi:10.1212/01.WNL.0000142424.65251.DB15477554
   PubMed Web of Science ®Google Scholar
• Pinessi L, Binello E, Martino PD, et al. The 1246 G/A polymorphism of the HCRTR2 gene is not associated with migraine. Cephalalgia. 2007;27(8):945–949. doi:10.1111/j.1468-2982.2007.01347.x17645762
   PubMed Web of Science ®Google Scholar
• Schürks M, Kurth T, Geissler I, Tessmann G, Diener HC, Rosskopf D. Cluster headache is associated with the G1246A polymorphism in the hypocretin receptor 2 gene. Neurology. 2006;66(12):1917–1919. doi:10.1212/01.wnl.0000215852.35329.3416554494
   PubMed Web of Science ®Google Scholar
• Rainero I, Gallone S, Rubino E, et al. Haplotype analysis confirms the association between the HCRTR2 gene and cluster headache. Headache. 2008;48(7):1108–1114. doi:10.1111/j.1526-4610.2008.01080.x18399985
   PubMed Web of Science ®Google Scholar
• Rainero I, Rubino E, Valfrè W, et al. Association between the G1246A polymorphism of the hypocretin receptor 2 gene and cluster headache: a meta-analysis. J Headache Pain. 2007;8(3):152. doi:10.1007/s10194-007-0383-x17563843
   PubMed Web of Science ®Google Scholar
• Annerbrink K, Westberg L, Olsson M, et al. Panic disorder is associated with the Val308Iso polymorphism in the hypocretin receptor gene. Psychiatr Genet. 2011;21(2):85–89. doi:10.1097/YPG.0b013e328341a3db21666548
   PubMed Web of Science ®Google Scholar
• Baumber L, Sjöstrand C, Leone M, et al. A genome-wide scan and HCRTR2 candidate gene analysis in a European cluster headache cohort. Neurology. 2006;66(12):1888–1893. doi:10.1212/01.wnl.0000219765.95038.d716801656
   PubMed Web of Science ®Google Scholar
• Schürks M, Limmroth V, Geissler I, et al. Association between migraine and the G1246A polymorphism in the hypocretin receptor 2 gene. Headache. 2007;47(8):1195–1199. doi:10.1111/j.1526-4610.2007.00863.x17883525
   PubMed Web of Science ®Google Scholar
• Schürks M, Kurth T, Geissler I, Tessmann G, Diener HC, Rosskopf D. The G1246A polymorphism in the hypocretin receptor 2 gene is not associated with treatment response in cluster headache. Cephalalgia. 2007;27(4):363–367. doi:10.1111/j.1468-2982.2007.01287.x17376114
   PubMed Web of Science ®Google Scholar
• Fourier C, Ran C, Steinberg A, Sjöstrand C, Waldenlind E, Belin AC. Analysis of HCRTR2 gene variants and cluster headache in Sweden. Headache. 2019;59(3):410–417. doi:10.1111/head.1346230652302
   PubMed Web of Science ®Google Scholar
• Cengiz M, Karaj V, Kocabasoğlu N, Gozubatik-Celik G, Dirican A, Bayoglu B. Orexin/hypocretin receptor, Orx1, gene variants are associated with major depressive disorder. Int J Psychiatry Clin Pract. 2019;23(2):114–121. doi:10.1080/13651501.2018.155154930596528
   PubMed Web of Science ®Google Scholar
• DSM-5 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Arlington: American Psychiatric Publishing; 2013.
   Google Scholar
• Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297–307. doi:10.1016/S1389-9457(00)00065-411438246
   PubMed Web of Science ®Google Scholar
• Firouzabadi N, Raeesi R, Zomorrodian K, Bahramali E, Yavarian I. Beta adrenoceptor polymorphism and clinical response to sertraline in major depressive patients. J Pharm Pharm Sci. 2017;16(20):1–7. doi:10.18433/J3W31F
   Google Scholar
• MWer S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215. doi:10.1093/nar/16.3.12153344216
   PubMed Web of Science ®Google Scholar
• Bonnet MH, Arand DL. Insomnia, metabolic rate and sleep restoration. J Intern Med. 2003;254(1):23–31. doi:10.1046/j.1365-2796.2003.01176.x12823640
   PubMed Web of Science ®Google Scholar
• Herring W, Budd K, Hutzelmann J, et al. Efficacy and tolerability of the dual orexin receptor antagonist MK-4305 in patients with primary insomnia: a randomized, controlled, adaptive crossover polysomnography study: O182. J Sleep Res. 2010;19:44–45.
   Google Scholar
• Winrow CJ, Gotter AL, Cox CD, et al. Promotion of sleep by suvorexant—a novel dual orexin receptor antagonist. J Neurogenet. 2011;25(1–2):52–61. doi:10.3109/01677063.2011.56695321473737
   PubMed Web of Science ®Google Scholar
• Van Den Pol AN, Gao XB, Obrietan K, Kilduff TS, Belousov AB. Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. J Neurosci. 1998;18(19):7962–7971. doi:10.1523/JNEUROSCI.18-19-07962.19989742163
   PubMed Web of Science ®Google Scholar
• Kohlmeier KA, Inoue T, Leonard CS. Hypocretin/orexin peptide signaling in the ascending arousal system: elevation of intracellular calcium in the mouse dorsal raphe and laterodorsal tegmentum. J Neurophysiol. 2004;92(1):221–235. doi:10.1152/jn.00076.200414999052
   PubMed Web of Science ®Google Scholar
• Yamanaka A, Tabuchi S, Tsunematsu T, Fukazawa Y, Tominaga M. Orexin directly excites orexin neurons through orexin 2 receptor. J Neurosci. 2010;30(38):12642–12652. doi:10.1523/JNEUROSCI.2120-10.201020861370
   PubMed Web of Science ®Google Scholar
• Nishizawa D, Kasai S, Hasegawa J, et al. Associations between the orexin (hypocretin) receptor 2 gene polymorphism Val308Ile and nicotine dependence in genome-wide and subsequent association studies. Mol Brain. 2015;8(1):50. doi:10.1186/s13041-015-0142-x26289589
   PubMed Web of Science ®Google Scholar
• De Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc National Acad Sci. 1998;95(1):322–327. doi:10.1073/pnas.95.1.322
   PubMed Web of Science ®Google Scholar
• Näsman J, Bart G, Larsson K, Louhivuori L, Peltonen H, Åkerman KE. The orexin OX1 receptor regulates Ca2+ entry via diacylglycerol-activated channels in differentiated neuroblastoma cells. J Neurosci. 2006;26(42):10658–10666. doi:10.1523/JNEUROSCI.2609-06.200617050705
   PubMed Web of Science ®Google Scholar
• Filizola M, Weinstein H. The study of G‐protein coupled receptor oligomerization with computational modeling and bioinformatics. FEBS J. 2005;272(12):2926–2938. doi:10.1111/j.1742-4658.2005.04730.x15955053
   PubMed Web of Science ®Google Scholar
• Guo W, Shi L, Filizola M, Weinstein H, Javitch JA. Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc National Acad Sci. 2005;102(48):17495–17500. doi:10.1073/pnas.0508950102
   PubMed Web of Science ®Google Scholar
• Kuehner C. Why is depression more common among women than among men? Lancet Psychiatry. 2017;4(2):146–158. doi:10.1016/S2215-0366(16)30263-227856392
   PubMed Web of Science ®Google Scholar
• Pu S, Jain MR, Kalra PS, Kalra SP. Orexins, a novel family of hypothalamic neuropeptides, modulate pituitary luteinizing hormone secretion in an ovarian steroid-dependent manner. Regul Pept. 1998;78(1–3):133–136. doi:10.1016/s0167-0115(98)00128-19879756
   PubMedGoogle Scholar
• Silveyra P, Lux-Lantos V, Libertun C. Both orexin receptors are expressed in rat ovaries and fluctuate with the estrous cycle: effects of orexin receptor antagonists on gonadotropins and ovulation. Am J Physiol Endocrinol Metab. 2007;293(4):E977–E985. doi:10.1152/ajpendo.00179.200717638707
   PubMed Web of Science ®Google Scholar
• Kok SW, Roelfsema F, Overeem S, et al. Pulsatile LH release is diminished, whereas FSH secretion is normal, in hypocretin-deficient narcoleptic men. Am J Physiol Endocrinol Metab. 2004;287(4):E630–E636. doi:10.1152/ajpendo.00060.200415172887
   PubMed Web of Science ®Google Scholar
• Weller CM, Wilbrink LA, Houwing-Duistermaat JJ, et al. Cluster headache and the hypocretin receptor 2 reconsidered: a genetic association study and meta-analysis. Cephalalgia. 2015;35(9):741–747. doi:10.1177/033310241455783925398231
   PubMed Web of Science ®Google Scholar
• Lu J, Zhao J, Balesar R, et al. Sexually dimorphic changes of hypocretin (orexin) in depression. EBioMedicine. 2017;1(18):311–319. doi:10.1016/j.ebiom.2017.03.043
   Web of Science ®Google Scholar
• Rudberg I, Hermann M, Refsum H, Molden E. Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharmacol. 2008;64(12):1181. doi:10.1007/s00228-008-0533-318677622
   PubMed Web of Science ®Google Scholar